Gemcitabine Combination Nano Therapies for Pancreatic Cancer

Pancreatic cancer is one of the deadliest causes of cancer-related death in the United States, with a 5-year overall survival rate of 6 to 8%. These statistics suggest that immediate medical attention is needed. Gemcitabine (GEM) is the gold standard first-line single chemotherapy agent for pancreat...

Descripción completa

Detalles Bibliográficos
Autores principales: Samanta, Kamalika, Setua, Saini, Kumari, Sonam, Jaggi, Meena, Yallapu, Murali M., Chauhan, Subhash C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920852/
https://www.ncbi.nlm.nih.gov/pubmed/31689930
http://dx.doi.org/10.3390/pharmaceutics11110574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920852/
https://www.ncbi.nlm.nih.gov/pubmed/31689930
http://dx.doi.org/10.3390/pharmaceutics11110574

Ejemplares similares